Global Health Drug Discovery Institute

What Global Health Drug Discovery Institute does

GHDDI is a Beijing-based, not-for-profit drug discovery institute founded in 2016 and inaugurated in 2017 through a Public-Private Partnership between the Bill & Melinda Gates Foundation, Tsinghua University, and the Beijing Municipal Government. The institute focuses on developing therapeutics for diseases disproportionately affecting developing countries — including tuberculosis, malaria, COVID-19, antimicrobial-resistant gram-negative infections, and rare diseases — areas where commercial incentives are weak. Its research footprint spans medicinal chemistry, structural biology, high-throughput screening (including access to the ReFRAME library of 12,000+ known drugs), computational chemistry, and AI-driven drug design.

Its core technology platform is AI KongMing (AI孔明), launched December 11, 2025, as China's first open, end-to-end AI drug discovery platform covering target identification through clinical candidate selection. The platform integrates proprietary generative AI molecular design models, high-precision virtual screening, multi-objective ADMET evaluation, and an LLM-based multi-agent engine, with deployment options including local and private cloud. Complementary products include the Targeting 2019-nCoV open data portal and a free AI virtual screening service for SARS-CoV-2. Pipeline candidates include GDI-4405 (a COVID-19 oral 3CLpro inhibitor co-developed with Hansoh Pharmaceutical, IND-approved by China's NMPA) and GDI-2 (a tuberculosis small-molecule inhibitor).

GHDDI operates as a grant-funded, mission-driven research institute. All drug discovery capabilities, compound libraries, and AI tools are provided free of charge to qualifying researchers and institutions worldwide. The institute reported 75,963,523.63 CNY (~$10.5M USD) in donations in 2024 from the Gates Foundation, Beijing Municipal Government, Tsinghua University, and other partners, and supplements this base with consortium funding (e.g., the $60M three-year Gr-ADI program with Gates, Novo Nordisk Foundation, and Wellcome). It serves a global customer base of academic researchers, pharmaceutical and biotech firms, and global health disease alliances, with over 40 institutional partners across more than 17 countries.

Name

Global Health Drug Discovery Institute

Legal name

北京华益全球健康药物研发中心

Website

https://ghddi.org

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

51–100 employees

Short description

GHDDI is a Beijing-based, Gates Foundation-, Tsinghua University-, and Beijing Municipal Government-backed not-for-profit drug discovery institute developing therapeutics and AI tools for global health diseases (tuberculosis, malaria, AMR, COVID-19) and offering free open access to academic researchers, pharma, and biotech worldwide.

Ownership category

akta.pro rank

Product category

Drug Discovery Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• AI drug discovery
• Global health therapeutics
• Nonprofit pharmaceutical research
• Infectious disease drug development
• Computational biology platforms

Headquarters

HQ city

Beijing

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Philanthropic/Grant Funding: As a nonprofit organization, GHDDI operates primarily through philanthropic grants and donations from founding partners. The institute received 75,963,523.63 Yuan in donated amounts in 2024, funded by the Gates Foundation, Beijing Municipal Government, Tsinghua University, and other partners.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels6 records

Core offering

GHDDI is a not-for-profit drug discovery institute that develops new therapeutics for diseases disproportionately affecting developing countries, including tuberculosis, malaria, COVID-19, and rare diseases. It operates the AI KongMing platform, providing end-to-end AI-driven drug design from target structure analysis to clinical candidate selection. All drug discovery capabilities, compound libraries, and AI platforms are offered free of charge to qualifying researchers worldwide under a Public-Private Partnership model.

Product overview

GHDDI operates as an AI-powered drug discovery institute offering an integrated platform called AI KongMing for end-to-end intelligent drug design. The platform spans from target structure analysis through AI-based molecular generation, activity screening, and druggability assessment. Supporting products include the Targeting 2019-nCoV data platform and Free AI Virtual Screening Service for COVID-19. The institute advances multiple drug candidates including GDI-4405 (COVID-19 antiviral) and GDI-2 (tuberculosis treatment). All offerings are oriented toward addressing global health diseases affecting developing nations.

Differentiator

Problem solved

Functional benefit

Brands

• AI KongMing: China's first domestically developed AI platform achieving end-to-end intelligent drug design, covering the full chain from target structure analysis to clinical candidate optimization for global health diseases including tuberculosis and malaria.

Products and services

• AI KongMing Platform (AI孔明) End-to-end AI-driven drug discovery platform covering target structure analysis, AI molecular generation and optimization, activity screening, and druggability assessment. Built to accelerate the development of drugs for global health diseases including tuberculosis, malaria, and viral infections. Offered as an open platform to global academia and industry.
• Targeting 2019-nCoV Platform AI-powered scientific research data and information sharing platform for coronavirus research. Archives historical SARS/MERS data, preclinical and clinical data resources, molecular chemical modeling, and real-time scientific research progress on 2019-nCoV. Openly accessible to researchers worldwide.
• Free AI Virtual Screening Service for COVID-19 Web-based AI-powered virtual screening tool for predicting SARS-CoV-2 target binding and phenotypic properties of queried compounds. Powered by Alibaba Cloud high-performance computing. Offered free of charge to worldwide research institutions investigating COVID-19 antiviral substances.
• GDI-4405 COVID-19 Oral Antiviral Candidate Pre-clinical oral antiviral candidate targeting SARS-CoV-2 3CL protease. Demonstrated greater inhibition potency than Pfizer's Nirmatrelvir in multiple assays with improved bioavailability and safety profile. Expected to enter clinical trials as part of strategic collaboration with Hansoh Pharmaceutical.
• GDI-2 Tuberculosis Drug Candidate Small molecule inhibitor for tuberculosis treatment. Has potential to significantly shorten TB treatment from standard 4-6 months to 1-2 months and provide new solutions for drug-resistant TB. Expected to become a preclinical drug candidate.

Quantifiable outcome

• Candidate molecule hit rates and optimization efficiency improved several-fold to orders-of-magnitude compared to conventional approaches in validated TB, malaria, and rare disease pipelines
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability9 records

Feature7 records

Partnerships

Twelve partnerships are on record, tiered core, flagship and minor.

• RTI InternationalcoreImplementation/ SI/ Consulting Partner · 26 January 2026Designated as external management partner for the Gr-ADI consortium, responsible for aligning efforts, ensuring effective coordination across 18 projects in 17 countries, and maintaining focus on the consortium's wider strategic objectives.
• Beijing Zhongguancun Academy and Zhongguancun Academy of Artificial Intelligence (中关村两院)flagshipStrategic or Co-development Partner · 5 September 2025Strategic partnership announced September 2025 focused on 'AI+制药'前沿交叉领域. Three pillars: joint talent cultivation with dual-mentor制度, joint AI+pharma lab共建 (multidimensional biomedical foundation models), and global health ecosystem building. Joint team has already identified candidate molecules against malaria targets.
• CEPI (Coalition for Epidemic Preparedness Innovations)coreStrategic or Co-development Partner · 2 August 2025GHDDI's novel adjuvant was selected for CEPI's 'Super Adjuvant Library,' supporting global vaccine development for emerging infectious diseases. This partnership connects GHDDI to CEPI's global vaccine R&D network.
• Hansoh Pharmaceutical (翰森制药)flagshipStrategic or Co-development Partner · 18 January 2023Strategic collaboration to develop COVID-19 oral 3CLpro inhibitor HS-10517, which received approval from China's National Medical Products Administration (NMPA) for clinical trial application. Represents GHDDI's first major technology transfer and co-development deal.
• European Coronavirus Drug Development ConsortiumminorStrategic or Co-development Partner · 18 August 2020GHDDI joined Europe's largest coronavirus drug R&D consortium to accelerate development of COVID-19 treatment solutions, contributing its screening platforms and compound library resources.
• Alibaba CloudcoreTechnology or Integration · 27 January 2020Provided computing resources and technical support for GHDDI's Targeting COVID-19 information sharing platform and Free AI Virtual Screening Service. Alibaba Cloud's high-performance computing (HPC) resources enabled exponentially accelerated molecular docking and deep learning computations.
• Tuberculosis Drug Accelerator (TBDA) PartnershipcoreStrategic or Co-development Partner · 24 October 2019GHDDI became the only member from China in the TBDA, joining 21 world-leading members including GSK, Merck, Bayer, Harvard, Cornell, Calibr at Scripps Research, and TB Alliance. Long-term goal is to create a TB drug regimen that cures patients in one month by 2024.
• Tsinghua UniversitycoreStrategic or Co-development Partner · 24 March 2017Co-founding partner providing scientific leadership, talent recruitment, research collaboration, operation management, and academic infrastructure. The School of Pharmaceutical Sciences (SPS) serves as the correspondent collaborator. Institute Director Dr. Sheng Ding serves concurrently as Dean of Tsinghua SPS.
• California Institute for Biomedical Research (Calibr)coreTechnology or Integration · 22 January 2016Strategic and technological partner providing expertise in early drug discovery and translational medicine. Calibr's运作模式 has been proven effective and GHDDI leverages Calibr's development experience and technology to build its own capabilities. GHDDI has already initiated several projects in collaboration with Calibr.
• MalDA (Medicines for Malaria Venture and partners)minorStrategic or Co-development PartnerGHDDI is the first Chinese member organization joining MalDA, contributing to global malaria drug development efforts.
• CARE (Cryptosporidium Infection Research Alliance)minorStrategic or Co-development PartnerGHDDI is the only representative in Asia at CARE, focused on cryptosporidium research and development.
• WHO China OfficeminorStrategic or Co-development PartnerWHO China Office and GHDDI co-hosted a symposium on ending tuberculosis in March 2024, demonstrating collaborative engagement on global health policy and research alignment.

Scale indicators9 records

Recent moves8 records

Expansion highlights6 records

Market position

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/theGHDDI
• Facebookfacebook.com/theGHDDI
• LinkedInlinkedin.com/company/ghddi

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Global Health Drug Discovery Institute